Jacqueline Palace

• Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.

  Sisay S. et al, (2017), J Neuroimmunol, 306, 40 - 45

• Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

  Jurynczyk M. et al, (2017), Brain, 140, 617 - 627

• Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.

  Tackley G. et al, (2017), J Neurol Neurosurg Psychiatry, 88, 165 - 169

• Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.

  Juryńczyk M. et al, (2017), J Neurol Neurosurg Psychiatry, 88, 132 - 136

• Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

  Geraldes R. et al, (2016), Brain Pathol

• Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status.

  Kong Y. et al, (2016), J Neurol Sci, 368, 84 - 88

• Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.

  Waters P. et al, (2016), J Neurol Neurosurg Psychiatry, 87, 1005 - 1015

• Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom.

  Rodríguez Cruz PM. et al, (2016), JAMA Neurol, 73, 954 - 960

• The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?

  Vermersch P. et al, (2016), Mult Scler, 22, 18 - 33

• Muscle magnetic resonance imaging in congenital myasthenic syndromes.

  Finlayson S. et al, (2016), Muscle Nerve, 54, 211 - 219

• Clinical features of the myasthenic syndrome arising from mutations in GMPPB.

  Rodríguez Cruz PM. et al, (2016), J Neurol Neurosurg Psychiatry, 87, 802 - 809

• Chronic pain disrupts the reward circuitry in multiple sclerosis.

  Seixas D. et al, (2016), Eur J Neurosci, 44, 1928 - 1934

• Atypical inflammatory demyelinating syndromes of the CNS.

  Hardy TA. et al, (2016), Lancet Neurol, 15, 967 - 981

• International consensus guidance for management of myasthenia gravis: Executive summary.

  Sanders DB. et al, (2016), Neurology, 87, 419 - 425

• Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment.

  Tackley G. et al, (2016), Mult Scler Relat Disord, 7, 21 - 25

• Myasthenia gravis: a clinical-immunological update.

  Binks S. et al, (2016), J Neurol, 263, 826 - 834

• Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.

  Huda S. et al, (2016), J Neurol Sci, 362, 66 - 68

• Systemic Vascular Disease Burden in Multiple Sclerosis: a post mortem case - control study

  Geraldes R. et al, (2016), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 42, 24 - 25

• MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

  Filippi M. et al, (2016), Lancet Neurol, 15, 292 - 303

• Fibrinogen deposition in the multiple sclerosis motor cortex

  Yates RL. et al, (2016), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 42, 33 - 33

• Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome.

  Allen NM. et al, (2016), Neurology, 86, 692 - 694

• The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.

  Duddy M. and Palace J., (2016), Pract Neurol, 16, 4 - 6

• Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

  McGuigan C. et al, (2016), J Neurol Neurosurg Psychiatry, 87, 117 - 125

• Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.

  Piccolo L. et al, (2016), J Neurol, 263, 370 - 379

• Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.

  Nour MM. et al, (2016), Neurology, 86, 79 - 87

• Therapeutic options in neuromyelitis optica spectrum disorders.

  Kitley J. and Palace J., (2016), Expert Rev Neurother, 16, 319 - 329

• Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

  Juryńczyk M. et al, (2016), J Neurol, 263, 140 - 149

• Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment.

  Pittock SJ. and Palace J., (2016), Handb Clin Neurol, 133, 165 - 183

• Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII α1 Chain.

  Logan CV. et al, (2015), Am J Hum Genet, 97, 878 - 885

• Antibodies to aquaporin-1 are not present in neuromyelitis optica.

  Schanda K. et al, (2015), Neurol Neuroimmunol Neuroinflamm, 2

• Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.

  McKee JB. et al, (2015), BMJ Open, 5

• Structural imaging of the cervical spinal cord with suppressed CSF signal using DANTE pulse trains.

  Li L. et al, (2015), Magn Reson Med, 74, 971 - 977

• A novel mutation in a patient with a DOK7 congenital myasthenic syndrome

  Willis T. et al, (2015), NEUROMUSCULAR DISORDERS, 25, S210 - S210

• Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.

  Rodríguez Cruz PM. et al, (2015), Neurology, 85, 1043 - 1047

• The influence of HLA-DRB1*15 on motor cortical neurodegeneration in multiple sclerosis

  Yates RL. et al, (2015), MULTIPLE SCLEROSIS JOURNAL, 21, 424 - 424

• Relapsing central nervous system demyelination in children with myelin oligodendrocyte glycoprotein (MOG) antibodies

  Hacohen Y. et al, (2015), MULTIPLE SCLEROSIS JOURNAL, 21, 88 - 89

• Neuromyelitis optica spectrum disorders and polyautoimmunity

  Correia AS. et al, (2015), MULTIPLE SCLEROSIS JOURNAL, 21, 655 - 656

• Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.

  Belaya K. et al, (2015), Brain, 138, 2493 - 2504

• A randomised, double-blind, placebo-controlled, multi-centre trial to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis optica: the PREVENT study

  Wingerchuk DM. et al, (2015), MULTIPLE SCLEROSIS JOURNAL, 21, 759 - 759

• Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease.

  Murchison A. et al, (2015), J Neurol Sci, 355, 49 - 53

• Update on biomarkers in neuromyelitis optica.

  Melamed E. et al, (2015), Neurol Neuroimmunol Neuroinflamm, 2

• Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO.

  Kitley J. et al, (2015), Neurol Neuroimmunol Neuroinflamm, 2

• Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

  Kremer S. et al, (2015), JAMA Neurol, 72, 815 - 822

• MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

  Waters P. et al, (2015), Neurol Neuroimmunol Neuroinflamm, 2

• Demographic and clinical features of neuromyelitis optica: A review.

  Pandit L. et al, (2015), Mult Scler, 21, 845 - 853

• Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

  Rodríguez Cruz PM. et al, (2015), JAMA Neurol, 72, 642 - 649

• Cardiac safety and tolerability of fingolimod in relapsing MS patients from the FIRST study who transitioned into the LONGTERMS study

  Palace JA. et al, (2015), EUROPEAN JOURNAL OF NEUROLOGY, 22, 254 - 254

• Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).

  Absoud M. et al, (2015), BMJ Open, 5

• What is Seronegative NMO?

  Palace J., (2015), MULTIPLE SCLEROSIS JOURNAL, 21, 801 - 802

• Placebo studies should not be undertaken in NMO--Yes.

  Palace J., (2015), Mult Scler, 21, 689 - 691

• Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

  Bennett JL. et al, (2015), Mult Scler, 21, 678 - 688

• MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.

  Matthews L. et al, (2015), J Neurol Neurosurg Psychiatry, 86, 537 - 542

• MRI in Leber's hereditary optic neuropathy:The relationship to multiple sclerosis

  Matthews L. et al, (2015), Journal of Neurology, Neurosurgery and Psychiatry, 86, 537 - 542

• Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.

  Palace J. et al, (2015), Lancet Neurol, 14, 497 - 505

• Challenges and opportunities in designing clinical trials for neuromyelitis optica.

  Weinshenker BG. et al, (2015), Neurology, 84, 1805 - 1815

• The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.

  Yates RL. et al, (2015), Neuropathol Appl Neurobiol, 41, 371 - 384

• The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis

  Yates RL. et al, (2015), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 41, 371 - 384

• Paediatric neuromyelitis optica: Clinical, MRI of the brain and prognostic features

  Absoud M. et al, (2015), Journal of Neurology, Neurosurgery and Psychiatry, 86, 470 - 472

• Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.

  Absoud M. et al, (2015), J Neurol Neurosurg Psychiatry, 86, 470 - 472

• Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children.

  Hacohen Y. et al, (2015), Neurol Neuroimmunol Neuroinflamm, 2

• Multiple sclerosis in Japan appears to be a milder disease compared to the UK

  Piccolo L. et al, (2015), Journal of Neurology, 262, 831 - 836

• MRI characteristics of neuromyelitis optica spectrum disorder: an international update.

  Kim HJ. et al, (2015), Neurology, 84, 1165 - 1173

• Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease

  Murchison A. et al, (2015), Journal of the Neurological Sciences, 355, 49 - 53

• Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.

  Juryńczyk M. et al, (2015), J Neurol Neurosurg Psychiatry, 86, 20 - 25

• Multiple sclerosis in Japan appears to be a milder disease compared to the UK.

  Piccolo L. et al, (2015), J Neurol, 262, 831 - 836

• Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.

  Matthews L. et al, (2015), PLoS One, 10

• Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: A clinical cohort study with natural history comparator

  Palace J. et al, (2015), The Lancet Neurology, 14, 497 - 505

• Neuroimmunology: Towards more-accurate diagnosis in neuromyelitis optica

  Fujihara K. and Palace J., (2014), Nature Reviews Neurology, 10, 679 - 681

• Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.

  Fujihara K. and Palace J., (2014), Nat Rev Neurol, 10, 679 - 681

• Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature

  Rodríguez Cruz PM. et al, (2014), Neuromuscular Disorders, 24, 1103 - 1110

• Congenital myopathies with secondary neuromuscular transmission defects; a case report and review of the literature.

  Rodríguez Cruz PM. et al, (2014), Neuromuscul Disord, 24, 1103 - 1110

• Late onset hereditary sensory and autonomic neuropathy with cognitive impairment associated with Y163X prion mutation

  Themistocleous AC. et al, (2014), Journal of Neurology, 261, 2230 - 2233

• Opportunistic infections of the retina in patients with aquaporin-4 antibody disease.

  George JS. et al, (2014), JAMA Neurol, 71, 1429 - 1432

• Late onset hereditary sensory and autonomic neuropathy with cognitive impairment associated with Y163X prion mutation.

  Themistocleous AC. et al, (2014), J Neurol, 261, 2230 - 2233

• Inherited disorders of the neuromuscular junction: an update.

  Rodríguez Cruz PM. et al, (2014), J Neurol, 261, 2234 - 2243

• A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.

  Dickens AM. et al, (2014), Neurology, 83, 1492 - 1499

• Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsing-remitting multiple sclerosis patients

  Sisay S. et al, (2014), JOURNAL OF NEUROIMMUNOLOGY, 275, 46 - 46

• Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders

  Cheng F. et al, (2014), JOURNAL OF NEUROIMMUNOLOGY, 275, 76 - 77

• Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres

  Waters P. et al, (2014), JOURNAL OF NEUROIMMUNOLOGY, 275, 15 - 15

• THE UK MS RISK-SHARING SCHEME: RESULTS FOR YEARS 4 AND 6

  Duddy M. et al, (2014), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 85

• PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

  Nour M. et al, (2014), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 85

• Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.

  Elsone L. et al, (2014), Mult Scler, 20, 1533 - 1540

• Congenital myasthenic syndromes and the neuromuscular junction.

  Rodríguez Cruz PM. et al, (2014), Curr Opin Neurol, 27, 566 - 575

• AMILORIDE CLINICAL TRIAL IN OPTIC NEURITIS: TRIAL PARADIGM

  McKee J. et al, (2014), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 85

• Treatments in NMO: current algorithms, future therapies and trial designs

  Palace J., (2014), MULTIPLE SCLEROSIS JOURNAL, 20, 6 - 7

• Neuromyelitis optica: annual relapse rates off and on immunosuppression and the relationship to attack type and ethnicity

  Tackley G. et al, (2014), MULTIPLE SCLEROSIS JOURNAL, 20, 352 - 353

• Multimodal clinical trial paradigm to assess neuroprotection in optic neuritis: baseline data

  Mckee JB. et al, (2014), MULTIPLE SCLEROSIS JOURNAL, 20, 361 - 361

• MRI study of Leber's hereditary optic neuropathy and MS suggests common lesion pathology and an 83% risk of MS-like lesions in females with LHON

  Matthews L. et al, (2014), MULTIPLE SCLEROSIS JOURNAL, 20, 170 - 171

• Inflammation does not cause chronic global neurodegeneration in NMO? A longitudinal multimodel quantitative MRI study comparing NMO and MS

  Matthews L. et al, (2014), MULTIPLE SCLEROSIS JOURNAL, 20, 282 - 282

• Magnetic resonance imaging in neuromyelitis optica.

  Tackley G. et al, (2014), Mult Scler, 20, 1153 - 1164

• Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.

  Kitley J. et al, (2014), JAMA Neurol, 71

• Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.

  Collongues N. et al, (2014), Mult Scler, 20, 1086 - 1094

• Modifying disability in progressive multiple sclerosis.

  Palace J. and Robertson N., (2014), Lancet, 383, 2189 - 2191

• Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials

  Kitley J. et al, (2014), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 85, 589 - U118

• Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.

  Kitley J. et al, (2014), J Neurol Neurosurg Psychiatry, 85, 589 - 590

• The role of imaging in diagnosing neuromyelitis optica spectrum disorder.

  Matthews LA. and Palace JA., (2014), Mult Scler Relat Disord, 3, 284 - 293

• The impact of neuromyelitis optica spectrum disorder on pregnancy outcome

  Nour MM. et al, (2014), EUROPEAN JOURNAL OF NEUROLOGY, 21, 758 - 758

• The impact of neuromyelitis optica spectrum disorder on pregnancy outcome

  Nour MM. et al, (2014), JOURNAL OF NEUROLOGY, 261, S487 - S487

• Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group.

  Norwood F. et al, (2014), J Neurol Neurosurg Psychiatry, 85, 538 - 543

• Inherited myasthenic syndromes

  Palace J. and Finlayson S., (2014), Oxford Textbook of Neuromuscular Disorders, 175 - 183

• Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.

  Kitley J. et al, (2014), J Neurol Sci, 339, 223 - 225

• Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab

  Kitley J. et al, (2014), Journal of the Neurological Sciences, 339, 223 - 225

• Erratum to: Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

  Wallner-Blazek M. et al, (2014), J Neurol, 261, 848 - 849

• Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

  Gold R. et al, (2014), J Neurol, 261

• UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model (BMJ Open (2014) 4, (e004073))

  Palace J. et al, (2014), BMJ Open, 4

• Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study

  Kitley J. et al, (2014), JAMA NEUROLOGY, 71, 276 - 283

• Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

  Kitley J. et al, (2014), JAMA Neurol, 71, 276 - 283

• Congenital myasthenic syndromes: Epidemiology, clinical phenotyping and aids to diagnosis in the neuromuscular clinic

  Healy EG. et al, (2014), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 40, 42 - 42

• Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

  Mealy MA. et al, (2014), JAMA Neurol, 71, 324 - 330

• Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

  Gold R. et al, (2014), J Neurol, 261, 267 - 276

• UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

  Palace J. et al, (2014), BMJ Open, 4

• UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model (BMJ Open (2014) 4, (e004073))

  Palace J. et al, (2014), BMJ Open, 4

• The role of imaging in diagnosing neuromyelitis optica spectrum disorder

  Matthews LA. and Palace JA., (2014), Multiple Sclerosis and Related Disorders, 3, 284 - 293

• Pain in multiple sclerosis: a systematic review of neuroimaging studies.

  Seixas D. et al, (2014), Neuroimage Clin, 5, 322 - 331

• Myasthenia in pregnancy: Best practice guidelines from a UK multispecialty working group

  Norwood F. et al, (2014), Journal of Neurology, Neurosurgery and Psychiatry, 85, 538 - 543

• Modifying disability in progressive multiple sclerosis

  Palace J. and Robertson N., (2014), The Lancet, 383, 2189 - 2191

• Erratum: Atypical idiopathic inflammatory demyelinating lesions: Prognostic implications and relation to multiple sclerosis (Journal of Neurology (2013) 260 (2016-2022) DOI: 10.1007/s00415-013-6918-y)

  Wallner-Blazek M. et al, (2014), Journal of Neurology, 261, 848 - 849

• Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neurology (2014) 261 (267-276) DOI: 10.1007/s00415-013-7115-8)

  Gold R. et al, (2014), Journal of Neurology, 261

• Congenital myasthenic syndromes and the neuromuscular junction

  Cruz PMR. et al, (2014), Current Opinion in Neurology, 27, 566 - 575

• Clinical commentary.

  Palace J., (2014), Mult Scler, 20

• Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study

  Gold R. et al, (2014), Journal of Neurology, 261, 267 - 276

• Acute, multifocal neurological symptoms

  Kitley J. et al, (2014), Imaging Acute Neurologic Disease: A Symptom-Based Approach, 209 - 227

• A novel cardiac phenotype in patients with GFPT1 or DPAGT1 mutations

  Lewis AJM. et al, (2014), Experimental and Clinical Cardiology, 20, 3139 - 3145

• Partnership and consent in MS treatment choice.

  Palace J., (2013), J Neurol Sci, 335, 5 - 8

• Partnership and consent in MS treatment choice

  Palace J., (2013), Journal of the Neurological Sciences, 335, 5 - 8

• Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.

  Kitley J. et al, (2013), JAMA Neurol, 70, 1375 - 1381

• Improving the model for the uk ms disease modifying treatment risk sharing scheme analysis: a new natural history dataset.

  Palace J. et al, (2013), J Neurol Neurosurg Psychiatry, 84

• DOK7 congenital myasthenic syndrome in childhood: Early diagnostic clues in 23 children

  Klein A. et al, (2013), Neuromuscular Disorders, 23, 883 - 891

• DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children.

  Klein A. et al, (2013), Neuromuscul Disord, 23, 883 - 891

• A decade of data for the uk multiple sclerosis risk-sharing scheme.

  Duddy M. and Palace J., (2013), J Neurol Neurosurg Psychiatry, 84

• Spinal cord MRI features in neuromyelitis optica (NMO): characteristics and relationship with severity and recovery in longitudinally extensive transverse myelitis (LETM) attacks

  Murchison AG. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 329 - 329

• Multiple sclerosis patients in Japan appear to have less disability compared to the UK

  Kumar G. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 341 - 341

• Modelling natural history for the UK multiple sclerosis risk-sharing scheme

  Palace J. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 339 - 339

• Microcystic inner nuclear layer pathology in aquaporin-4 antibody-positive patients

  George J. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 432 - 433

• Long term efficacy, adherence and reasons for discontinuation in 103 cases of neuromyelitis optica treated with azathioprine: a multicentre study from the United Kingdom

  Elsone L. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 446 - 447

• Is azathioprine effective in highly-active neuromyelitis optica? A multicentre study from the United Kingdom

  Elsone L. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 233 - 233

• Improved MRI-derived assessment of grey and white matter volumes by using SIENAX

  Battaglini M. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 424 - 425

• Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.

  Finlayson S. et al, (2013), J Neurol Neurosurg Psychiatry, 84, 1119 - 1125

• Brain atrophy and lesion load predict long term disability in multiple sclerosis.

  Popescu V. et al, (2013), J Neurol Neurosurg Psychiatry, 84, 1082 - 1091

• Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders

  Kitley J. et al, (2013), MULTIPLE SCLEROSIS JOURNAL, 19, 83 - 84

• Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.

  Kitley J. et al, (2013), J Neurol Neurosurg Psychiatry, 84, 918 - 921

• Low Myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica

  Ciccarelli O. et al, (2013), Annals of Neurology, 74, 301 - 305

• Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica.

  Ciccarelli O. et al, (2013), Ann Neurol, 74, 301 - 305

• Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

  Wallner-Blazek M. et al, (2013), J Neurol, 260, 2016 - 2022

• Atypical idiopathic inflammatory demyelinating lesions: Prognostic implications and relation to multiple sclerosis

  Wallner-Blazek M. et al, (2013), Journal of Neurology, 260, 2016 - 2022

• Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

  Matthews L. et al, (2013), Neurology, 80, 1330 - 1337

• Congenital myasthenic syndromes: an update.

  Finlayson S. et al, (2013), Pract Neurol, 13, 80 - 91

• Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.

  Cossins J. et al, (2013), Brain, 136, 944 - 956

• Telephone Assessment of the Expanded Disability Status Scale

  Huda S. and Palace J., (2013), NEUROLOGY, 80

• Characterization of NMO and NMOSD Patients with a Late Onset

  Collongues N. et al, (2013), NEUROLOGY, 80

• ASIC1 Blockade in Primary Progressive Multiple Sclerosis: Evidence of Neuroprotection with Amiloride

  Arun T. et al, (2013), NEUROLOGY, 80

• Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica

  Kitley J. et al, (2013), NEUROLOGY, 80

• Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.

  Finlayson S. et al, (2013), Muscle Nerve, 47, 279 - 282

• Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

  Arun T. et al, (2013), Brain, 136, 106 - 115

• Targeting ASIC1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride

  Arun T. et al, (2013), Brain, 136, 106 - 115

• Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies

  Kitley J. et al, (2013), Journal of Neurology, Neurosurgery and Psychiatry, 84, 918 - 921

• Congenital myasthenic syndromes due to mutations in ALG2 and ALG14

  Cossins J. et al, (2013), Brain, 136, 944 - 956

• Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1

  Finlayson S. et al, (2013), Journal of Neurology, Neurosurgery and Psychiatry, 84, 1119 - 1125

• Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.

  Gnanapavan S. et al, (2013), PLoS One, 8

• The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis.

  Gelineau-Morel R. et al, (2012), Hum Brain Mapp, 33, 2802 - 2814

• Identification of DPAGT1 as a new gene in which mutations cause a congenital myasthenic syndrome.

  Belaya K. et al, (2012), Ann N Y Acad Sci, 1275, 29 - 35

• DOK7 congenital myasthenic syndrome.

  Palace J., (2012), Ann N Y Acad Sci, 1275, 49 - 53

• Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.

  Jacob A. et al, (2012), Mult Scler, 18, 1801 - 1803

• Neuroplasticity and functional recovery in multiple sclerosis.

  Tomassini V. et al, (2012), Nat Rev Neurol, 8, 635 - 646

• Neuroplasticity and functional recovery in multiple sclerosis

  Tomassini V. et al, (2012), Nature Reviews Neurology, 8, 635 - 646

• NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT

  George J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND

  Luppe S. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES

  Kitley J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS: A VARIETY OF CAUSES SEEN WITHIN THE NATIONAL NEUROMYELITIS OPTICA SERVICE

  Kitley J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• FAST CHANNEL CONGENITAL MYASTHENIA: REVIEW OF 12 CASES AND TREATMENT CHALLENGES

  Finlayson S. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83, A23 - A23

• Treatment of neuromyelitis optica: Review and recommendations

  Kimbrough DJ. et al, (2012), Multiple Sclerosis and Related Disorders, 1, 180 - 187

• Treatment of Neuromyelitis Optica: Review and Recommendations.

  Kimbrough DJ. et al, (2012), Mult Scler Relat Disord, 1, 180 - 187

• The differential diagnoses of patients presenting with longitudinally extensive transverse myelitis: analysis of 76 cases

  Kitley J. et al, (2012), MULTIPLE SCLEROSIS JOURNAL, 18, 68 - 68

• The association between sunlight hours and month of birth in multiple sclerosis patients across UK regions

  Matthews LAE. et al, (2012), MULTIPLE SCLEROSIS JOURNAL, 18, 375 - 376

• Seasonal pattern of variation in neuromyelitis optica relapses

  Elsone L. et al, (2012), MULTIPLE SCLEROSIS JOURNAL, 18, 292 - 292

• Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort

  Leonard HAC. et al, (2012), MULTIPLE SCLEROSIS JOURNAL, 18, 291 - 292

• Neuromyelitis optica spectrum disorder and multiple sclerosis can be distinguished on the basis of MRI brain lesion characteristics

  Matthews LAE. et al, (2012), MULTIPLE SCLEROSIS JOURNAL, 18, 9 - 10

• Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica

  Sedani S. et al, (2012), MULTIPLE SCLEROSIS JOURNAL, 18, 296 - 297

• A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology.

  Kolasinski J. et al, (2012), Brain, 135, 2938 - 2951

• Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

  Kitley J. et al, (2012), Neurology, 79, 1273 - 1277

• Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease.

  Pitceathly RD. et al, (2012), Neurology, 79, 1145 - 1154

• Work in progress: quality of life (QoL) and neurological disease - trajectories of outcome in neurological conditions (TONiC): a study protocol

  Gibbons CJ. et al, (2012), EUROPEAN JOURNAL OF NEUROLOGY, 19, 264 - 264

• Therapy of myasthenic syndrome

  Palace J., (2012), EUROPEAN JOURNAL OF NEUROLOGY, 19, 824 - 824

• A practical guide to the treatment of neuromyelitis optica.

  Palace J. et al, (2012), Pract Neurol, 12, 209 - 214

• Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis.

  Popescu V. et al, (2012), Neuroimage, 61, 1484 - 1494

• Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.

  Belaya K. et al, (2012), Am J Hum Genet, 91, 193 - 201

• Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates

  Belaya K. et al, (2012), American Journal of Human Genetics, 91, 193 - 201

• The association of multiple sclerosis with bullous pemphigoid: is there a shared antigen response?

  Taghipour K. et al, (2012), J Am Acad Dermatol, 67, 160 - 161

• Relating brain damage to brain plasticity in patients with multiple sclerosis.

  Tomassini V. et al, (2012), Neurorehabil Neural Repair, 26, 581 - 593

• Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects

  Bibani RH. et al, (2012), Multiple Sclerosis and Related Disorders, 1, 131 - 135

• Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects.

  Bibani RH. et al, (2012), Mult Scler Relat Disord, 1, 131 - 135

• Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study

  Kappos L. et al, (2012), JOURNAL OF NEUROLOGY, 259, S64 - S65

• Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.

  Kitley J. et al, (2012), Brain, 135, 1834 - 1849

• Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients

  Gold R. et al, (2012), JOURNAL OF NEUROLOGY, 259, S69 - S69

• Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.

  Leite MI. et al, (2012), Neurology, 78, 1601 - 1607

• Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.

  Guergueltcheva V. et al, (2012), J Neurol, 259, 838 - 850

• Influence of pregnancy on neuromyelitis optica spectrum disorder.

  Kim W. et al, (2012), Neurology, 78, 1264 - 1267

• Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?

  Downer JJ. et al, (2012), Neuroradiology, 54, 279 - 285

• Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?

  Downer JJ. et al, (2012), Neuroradiology, 54, 279 - 285

• Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS

  Comi G. et al, (2012), NEUROLOGY, 78

• TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE

  Elsone L. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• The spectrum of mutations that underlie the DOK7 neuromuscular junction synaptopathy, and the patient response to treatment

  Beeson D. et al, (2012), NEUROMUSCULAR DISORDERS, 22, S16 - S16

• The differential diagnosis of longitudinally extensive transverse myelitis.

  Kitley JL. et al, (2012), Mult Scler, 18, 271 - 285

• THE CLINICAL PHENOTYPIC SPECTRUM OF GFPT1 ASSOCIATED CONGENITAL MYASTHENIC SYNDROME

  Chaouch A. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• THE ASSOCIATION OF TWO RARE NEUROLOGICAL DISEASES: A MULTICENTRE STUDY OF 16 PATIENTS WITH ACHR ANTIBODY MYASTHENIA GRAVIS AND AQP4 ANTIBODY NEUROMYELITIS OPTICA SPECTRUM DISORDER

  Leite MI. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• MYELIN-OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY AS A CAUSE OF ACUTE DISSEMINATED ENCEPHALOMYELITIS WITH A NEUROMYELITIS OPTICA-LIKE PHENOTYPE IN ADULTS

  Kitley J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• Myelin water imaging reflects clinical variability in multiple sclerosis.

  Kolind S. et al, (2012), Neuroimage, 60, 263 - 270

• Myelin water imaging reflects clinical variability in multiple sclerosis

  Kolind S. et al, (2012), NeuroImage, 60, 263 - 270

• DIFFERENCES IN OUTCOMES IN NEUROMYELITIS OPTICA BETWEEN A JAPANESE COHORT AND A PREDOMINANTLY CAUCASIAN COHORT FROM THE UK

  Kitley J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• COMPARISON OF HISTOLOGICAL AND DIFFUSION-WEIGHTED MRI TECHNIQUES IN THE ANALYSIS OF POST MORTEM MULTIPLE SCLEROSIS BRAINS

  Kolasinski J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• CAN MRI BE USED AS A DIAGNOSTIC TOOL IN NEUROMYELITIS OPTICA SPECTRUM DISORDER?

  Matthews L. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• AQUAPORIN 4 ANTIBODY SEROPOSITIVITY AND VISUAL FUNCTION IN A UK COHORT

  George J. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• AMILORIDE TREATMENT AMELIORATES MRI SURROGATE MARKERS OF NEURODEGENERATION IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  Arun T. et al, (2012), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83

• Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

  Waters PJ. et al, (2012), Neurology, 78, 665 - 671

• Clinical features in a series of fast channel congenital myasthenia syndrome.

  Palace J. et al, (2012), Neuromuscul Disord, 22, 112 - 117

• Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan

  Kitley J. et al, (2012), Brain, 135, 1834 - 1849

• Prognostic factors in aquaporin-4 antibody-mediated disease: UK and Japanese cohorts

  Kitley J. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S291 - S291

• Myelin-oligodendrocyte glycoprotein antibody-mediated acute inflammatory demyelinating disease mimicking neuromyelitis optica

  Kitley J. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S281 - S281

• Early clinical predictors of disease progression in relapsing-remitting multiple sclerosis: the Oxford UK cohort

  Wakerley BR. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S296 - S297

• Distinction of aquaporin-4 antibody positive neuromyelitis optica from multiple sclerosis using diffusion tensor and myelin water imaging

  Matthews L. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S165 - S165

• Autoimmunity to astrocytes in multiple sclerosis and EAE

  Amor S. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S122 - S122

• Aquaporin 4 antibody seropositivity and visual function in a UK cohort

  George J. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S493 - S494

• Acid-sensing ion channel 1 blockade preserves brain microstructural integrity in patients with multiple sclerosis

  de Ruiter MB. et al, (2011), MULTIPLE SCLEROSIS JOURNAL, 17, S205 - S205

• Use of mitoxantrone in neuromyelitis optica.

  Kitley JL. et al, (2011), Arch Neurol, 68

• Acute disseminated encephalomyelitis and its place amongst other acute inflammatory demyelinating CNS disorders.

  Palace J., (2011), J Neurol Sci, 306, 188 - 191

• MRI assessment of iron deposition in multiple sclerosis.

  Ropele S. et al, (2011), J Magn Reson Imaging, 34, 13 - 21

• The diagnostic conundrum of primary angiitis of the central nervous system: a case report.

  Gill D. et al, (2011), J Neurol, 258, 925 - 928

• Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.

  Senderek J. et al, (2011), Am J Hum Genet, 88, 162 - 172

• Authors' reply to BioMarin Europe

  Nicholl DJ. et al, (2011), BMJ, 342

• Orphan drugs Authors' reply to BioMarin Europe

  Nicholl DJ. et al, (2011), BRITISH MEDICAL JOURNAL, 342

• Preservation of motor skill learning in patients with multiple sclerosis.

  Tomassini V. et al, (2011), Mult Scler, 17, 103 - 115

• Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations

  Guergueltcheva V. et al, (2011), Journal of Neurology, 1 - 13

• Clinical features in a series of fast channel congenital myasthenia syndrome

  Palace J. et al, (2011), Neuromuscular Disorders

• Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia.

  Munot P. et al, (2010), Neuromuscul Disord, 20, 796 - 800

• Orphan Drugs Open letter to prime minister David Cameron and health secretary Andrew Lansley

  Nicholl DJ. et al, (2010), BRITISH MEDICAL JOURNAL, 341

• Open letter to prime minister David Cameron and health secretary Andrew Lansley.

  Nicholl DJ. et al, (2010), BMJ, 341

• PREDICTING BRAIN ATROPHY AT 1 YEAR BY BASELINE MULTIMODAL MRI DATA

  Tarunya A. et al, (2010), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 81, E42 - E42

• DIRECT COMPARISON OF MULTIPLE NONLESIONAL IMAGING MEASURES TO ASSESS THEIR POWER TO MEASURE TREATMENT EFFECTS OVER 1 YEAR IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  Arun T. et al, (2010), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 81, E52 - E53

• COMPARING MRI MEASURES OF MYELIN INTEGRITY AS SURROGATE MARKERS FOR THE CLINICAL EXPRESSION OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  Matthews L. et al, (2010), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 81, E56 - E56

• AQUAPORIN-4 M 23 ISOFORM PROVIDES A MORE SENSITIVE ASSAY FOR AQUAPORIN-4 ANTIBODIES

  Waters P. et al, (2010), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 81, E32 - E32

• "THE EYES HAVE IT": INITIAL GENETIC SCREENING IN SUSPECTED CONGENITAL MYASTHENIA

  Lashley D. et al, (2010), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 81, E63 - E63

• Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

  Sørensen PS. et al, (2010), 1, 63 - 74

• Congenital myasthenia: contrasting rapsyn and Dok-7 phenotypes

  Palace J., (2010), EUROPEAN JOURNAL OF NEUROLOGY, 17, 628 - 628

• Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels.

  Stagg CJ. et al, (2010), Epilepsia, 51, 1898 - 1901

• Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.

  Palace J. et al, (2010), Arch Neurol, 67, 1016 - 1017

• Clinical aspects of myasthenia explained.

  Verschuuren JJ. et al, (2010), Autoimmunity, 43, 344 - 352

• Intercenter differences in diffusion tensor MRI acquisition.

  Pagani E. et al, (2010), J Magn Reson Imaging, 31, 1458 - 1468

• Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

  Lashley D. et al, (2010), Neurology, 74, 1517 - 1523

• Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms

  Cossins J. et al, (2010), NEUROMUSCULAR DISORDERS, 20, S18 - S18

• MRI criteria for MS in patients with clinically isolated syndromes.

  Montalban X. et al, (2010), Neurology, 74, 427 - 434

• Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis.

  Giorgio A. et al, (2010), J Magn Reson Imaging, 31, 309 - 316

• Open letter to prime minister David Cameron and health secretary Andrew Lansley.

  Nicholl DJ. et al, (2010), BMJ (Clinical research ed.), 341

• Modafinil for multiple sclerosis fatigue: does it work?

  Littleton ET. et al, (2010), Clin Neurol Neurosurg, 112, 29 - 31

• Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.

  Boggild M. et al, (2009), BMJ, 339

• The borderland of neuromyelitis optica.

  Matthews LA. et al, (2009), Pract Neurol, 9, 335 - 340

• Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy.

  Palace J., (2009), J Neurol Sci, 286, 24 - 27

• THE THALAMUS AND NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS

  Seixas D. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• SEX RATIO IN AN OXFORD BASED STUDY OF MULTIPLE SCLEROSIS PATIENTS

  Matthews L. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• SERUM ANTIBODIES IN EPILEPSY

  Brenner T. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• SERUM ANTIBODIES IN EPILEPSY

  Brenner T. et al, (2009), EPILEPSIA, 50, 484 - 485

• NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT

  Leite MI. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• MOTOR SKILL LEARNING IN MULTIPLE SCLEROSIS

  Tomassini V. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• LONG TERM OUTCOME IN NEUROMYELITIS OPTICA: LESSONS FROM 6 YEARS OF THE UK NMO STUDY

  Jacob A. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• LATE ADULT ONSET TEMPORAL LOBE EPILEPSY WITH ANTIBODIES TO VOLTAGE GATED POTASSIUM CHANNELS

  Matthews L. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• EPHEDRINE TREATMENT RESULTS IN PROFOUND FUNCTIONAL IMPROVEMENTS IN DOK-7 CONGENITAL MYASTHENIA

  Lashley D. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• CLINICAL FEATURES OF THE SLOW-CHANNEL CONGENITAL MYASTHENIC SYNDROME

  Lashley D. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

• The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis

  Clerico M. et al, (2009), MULTIPLE SCLEROSIS, 15, S137 - S138

• PLS models discriminate types of MS from spectroscopic analysis of plasma and urinele

  Dickens AM. et al, (2009), MULTIPLE SCLEROSIS, 15, S275 - S275

• Multiple sclerosis lesions: insights from imaging techniques.

  Tomassini V. and Palace J., (2009), Expert Rev Neurother, 9, 1341 - 1359

• MS patients with chronic pain have more myelin water and less heterogeneous T1 values in normal-appearing white matter than matched MS patients without pain

  Kolind S. et al, (2009), MULTIPLE SCLEROSIS, 15, S209 - S209

• Functional correlates of motor learning in multiple sclerosis

  Tomassini V. et al, (2009), MULTIPLE SCLEROSIS, 15, S96 - S96

• Functional connectivity changes of the motor network in patients with multiple sclerosis: a multicentre fMRI study

  Rocca M. et al, (2009), MULTIPLE SCLEROSIS, 15, S99 - S99

• Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis.

  Cader S. et al, (2009), J Psychopharmacol, 23, 686 - 696

• Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study.

  Rocca MA. et al, (2009), Hum Brain Mapp, 30, 2412 - 2425

• Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodies.

  Littleton E. et al, (2009), Mol Cell Proteomics, 8, 1688 - 1696

• To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis

  Clerico M. et al, (2009), JOURNAL OF NEUROLOGY, 256, S11 - S11

• Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.

  Viegas S. et al, (2009), J Neurol Neurosurg Psychiatry, 80, 679 - 682

• Functional connectivity changes of the motor network in patients with multiple sclerosis: a multi-centre fMRI study

  Filippi M. et al, (2009), JOURNAL OF NEUROLOGY, 256, S47 - S48

• T Cell-Mediated Autoimmune Disease Due to Low-Affinity Crossreactivity to Common Microbial Peptides (DOI:10.1016/j.immuni.2009.01.009)

  Harkiolaki M. et al, (2009), Immunity, 30

• THE OXFORD EXPERIENCE OF THYMOMA SURGERY IN PATIENTS WITH MG: 1998-2007

  Viegas S. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80, 452 - 452

• Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis.

  Mancini L. et al, (2009), Neuroimage, 45, 500 - 511

• SERUM AUTOANTIBODIES TO GLUTAMIC ACID DECARBOXYLASE ARE ASSOCIATED WITH REDUCED CORTICAL GABA LEVELS IN PATIENTS WITH EPILEPSY

  Stagg CJ. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80, 463 - 463

• OUTPATIENT TARGETS: TOWARDS A FASTER TRACK SYSTEM

  Bosnell RA. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80, 457 - 457

• EVIDENCE OF SUBCORTICAL ATROPHY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  Arun T. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80, 463 - 463

• Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?

  Korteweg T. et al, (2009), Mult Scler, 15, 465 - 471

• BEFORE AND AFTER THE ACUTE MS LESION: A LONGITUDINAL DTI STUDY

  Giorgio A. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80, 463 - 463

• T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides.

  Harkiolaki M. et al, (2009), Immunity, 30, 348 - 357

• Guidelines for differential diagnosis of suspected multiple sclerosis.

  Palace J., (2009), Nat Clin Pract Neurol, 5, 134 - 135

• The multiple sclerosis risk sharing scheme monitoring study - Early results and lessons for the future

  Pickin M. et al, (2009), BMC Neurology, 9

• The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.

  Pickin M. et al, (2009), BMC Neurol, 9

• The effect of dok-7 on acetylcholine receptor clustering in C2C12 cells

  Spearman H. et al, (2008), NEUROMUSCULAR DISORDERS, 18, 748 - 748

• The congenital myasthenic syndromes.

  Palace J. and Beeson D., (2008), J Neuroimmunol, 201-202, 2 - 5

• Congenital myasthenic syndromes in childhood: diagnostic and management challenges.

  Kinali M. et al, (2008), J Neuroimmunol, 201-202, 6 - 12

• The UK long-term cost-effectiveness study of disease-modifying therapies in multiple sclerosis: lessons from tire first analysis

  Palace J. et al, (2008), MULTIPLE SCLEROSIS, 14, S171 - S171

• Optimizing diffusion measurements for large-scale, multicenter multiple sclerosis trials: a pan-European study

  Rovaris M. et al, (2008), MULTIPLE SCLEROSIS, 14, S216 - S216

• Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis

  Clerico M. et al, (2008), MULTIPLE SCLEROSIS, 14, S61 - S61

• Reproducibility of fMRI in the clinical setting: implications for trial designs.

  Bosnell R. et al, (2008), Neuroimage, 42, 603 - 610

• Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.

  Waters P. et al, (2008), Arch Neurol, 65, 913 - 919

• Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

  Clerico M. et al, (2008), Cochrane database of systematic reviews (Online)

• Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis

  Clerico M. et al, (2008), JOURNAL OF NEUROLOGY, 255, 37 - 37

• Optimising diffusion measurements for large-scale, multicentre multiple sclerosis trials: a pan-European study

  Perego E. et al, (2008), JOURNAL OF NEUROLOGY, 255, 84 - 84

• Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition.

  Manson SC. et al, (2008), Exp Brain Res, 187, 25 - 31

• Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

  Clerico M. et al, (2008), Cochrane Database Syst Rev

• The evolving clinical spectrum of neuromyelitis optica

  Viegas SD. et al, (2008), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 79, 344 - 344

• Neuroprotection and repair.

  Palace J., (2008), J Neurol Sci, 265, 21 - 25

• Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study.

  Wegner C. et al, (2008), Eur J Neurol, 15, 113 - 122

• MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings.

  Seewann A. et al, (2008), J Neurol, 255, 1 - 10

• Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

  Tzartos JS. et al, (2008), Am J Pathol, 172, 146 - 155

• Congenital myasthenic syndromes and the formation of the neuromuscular junction.

  Beeson D. et al, (2008), Ann N Y Acad Sci, 1132, 99 - 103

• Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy.

  Blamire AM. et al, (2007), Magn Reson Med, 58, 880 - 885

• Neuromyelitis optica and longitudinally extensive transverse myelitis following thymectomy for myasthenia gravis

  Jarius S. et al, (2007), MULTIPLE SCLEROSIS JOURNAL, 13, S159 - S159

• Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing

  Jarius S. et al, (2007), MULTIPLE SCLEROSIS, 13, S158 - S158

• Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials

  Clerico M. et al, (2007), MULTIPLE SCLEROSIS, 13, S92 - S92

• Transcranial direct current stimulation: A potential tool for rehabilitation?

  Stagg CJ. et al, (2007), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 78, 1036 - 1036

• Prevalence and geographical distribution of UK congenital myasthenic syndrome patients referred to the oxford national specialist commissioning advisory group service

  Lashley D. et al, (2007), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 78, 1020 - 1020

• Diffusion tensor imaging defines subregions of human lateral premotor cortex with distinct frontoparietal connections

  Tomassini V. et al, (2007), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 78, 1028 - 1028

• A novel sensitive assay for aqueporin-4 antibodies (NMO-IgG)

  Waters P. et al, (2007), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 78, 1030 - 1030

• Inflammation versus neurodegeneration: consequences for treatment.

  Palace J., (2007), J Neurol Sci, 259, 46 - 49

• Clinical features of the DOK7 neuromuscular junction synaptopathy.

  Palace J. et al, (2007), Brain, 130, 1507 - 1515

• Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis.

  Cader S. et al, (2007), Neuroimage, 36, 19 - 27

• White matter changes in Leber's hereditary optic neuropathy: MRI findings.

  Küker W. et al, (2007), Eur J Neurol, 14, 591 - 593

• Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy

  Clerico M. et al, (2007), JOURNAL OF NEUROLOGY, 254, 165 - 165

• Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.

  Paul F. et al, (2007), PLoS Med, 4

• NMO-IgG in the diagnosis of neuromyelitis optica.

  Jarius S. et al, (2007), Neurology, 68, 1076 - 1077

• Towards defining antigenic targets for antibodies in multiple sclerosis

  Littleton ET. et al, (2006), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 77, 1399 - 1400

• Mutations in dok-7 underlie a congenital myasthenic syndrome with a (sic)Limb girdle broken vertical bar pattern of muscle weakness.

  Beeson D. et al, (2006), ANNALS OF NEUROLOGY, 60, 640 - 640

• Loss of interhemispheric inhibition in patients with multiple sclerosis is related to corpus callosum atrophy.

  Manson SC. et al, (2006), Exp Brain Res, 174, 728 - 733

• Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations.

  Cossins J. et al, (2006), Brain, 129, 2773 - 2783

• Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations

  Cossins J. et al, (2006), Brain, 129, 2773 - 2783

• Dok-7 mutations underlie a neuromuscular junction synaptopathy.

  Beeson D. et al, (2006), Science, 313, 1975 - 1978

• Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.

  Wegner C. et al, (2006), Neurology, 67, 960 - 967

• Running a mitoxantrone service for multiple sclerosis

  Craner MI. et al, (2006), MULTIPLE SCLEROSIS, 12, S211 - S211

• Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis

  Clerico M. et al, (2006), MULTIPLE SCLEROSIS, 12, S128 - S128

• MRI in Leber's optic neuropathy with multiple sclerosis (Harding's disease)

  Kuker W. et al, (2006), MULTIPLE SCLEROSIS, 12, S165 - S165

• Interleukin-17 expression in multiple sclerosis

  Tzartos JS. et al, (2006), JOURNAL OF NEUROIMMUNOLOGY, 178, 201 - 201

• An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica

  Littleton ET. et al, (2006), MULTIPLE SCLEROSIS, 12, S156 - S156

• APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers.

  Burwick RM. et al, (2006), Neurology, 66, 1373 - 1383

• A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis

  Clerico M. et al, (2006), JOURNAL OF NEUROLOGY, 253, 127 - 127

• Reduced brain functional reserve and altered functional connectivity in patients with multiple sclerosis.

  Cader S. et al, (2006), Brain, 129, 527 - 537

• Effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with multiple sclerosis

  Burke G. et al, (2006), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 77, 130 - 130

• A nationwide service for the diagnosis and treatment of congenital myasthenic syndromes

  Burke G. et al, (2006), DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 48, 5 - 5

• Serum antibodies in epilepsy and seizure-associated disorders.

  McKnight K. et al, (2005), Neurology, 65, 1730 - 1736

• Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.

  Sørensen PS. et al, (2005), Eur J Neurol, 12, 817 - 827

• Viral vectors for immunisation against potassium channel Kv1.2

  McKnight KM. et al, (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 1321 - 1321

• Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate

  Clerico M. et al, (2005), MULTIPLE SCLEROSIS, 11, S111 - S112

• The genetic diagnosis of congenital myasthenic syndromes (CMS)

  Man S. et al, (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 1324 - 1325

• The evaluation of a novel "goat serum" therapy (Aimspro) in multiple sclerosis

  Burke G. et al, (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 1326 - 1326

• Neuropathological features of multiple sclerosis (MS) can be seen in a humanised mouse model of EAE with heterogeneous clinical aspects

  Tzartos JS. et al, (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 1320 - 1320

• Effect of sildenafil citrate on CBF and BOLD activation in multiple sclerosis patients

  Manson SC. et al, (2005), MULTIPLE SCLEROSIS, 11, S59 - S59

• An audit of the use of Modafinil in clinical practice for the treatment of fatigue in multiple sclerosis patients

  Littleton ET. and Palace J., (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 1316 - 1316

• A case of MS, ADEM, NMO or all three?

  Pomeroy IM. et al, (2005), MULTIPLE SCLEROSIS, 11, S20 - S20

• MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS).

  Fazekas F. et al, (2005), Mult Scler, 11, 433 - 440

• Sjogren's myelopathy

  Mukhtyar C. et al, (2005), RHEUMATOLOGY, 44, I120 - I121

• The management of myasthenia gravis

  Hilton-Jones D. and Palace J., (2005), Practical Neurology, 5, 18 - 27

• Typical cortical lesions in an animal model of MS

  Pomeroy IM. et al, (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 152 - 152

• Synaptic loss and impaired synaptic plasticity in cortical lesions of multiple sclerosis

  Wegner C. et al, (2005), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76, 152 - 152

• Serum antibodies in patients with epilepsy

  Lang B. et al, (2005), EPILEPSIA, 46, 76 - 76

• Myasthenia gravis and Lambert-Eaton myasthenic syndrome

  Palace J. and Hilton-Jones D., (2004), Medicine, 32, 114 - 118

• Reduced growth associated protein-43 and synaptic loss in cortical lesions of multiple sclerosis

  Wegner C. et al, (2004), MULTIPLE SCLEROSIS, 10, S155 - S155

• Patient choice and adherence with disease-modifying therapy in multiple sclerosis

  Burke G. et al, (2004), MULTIPLE SCLEROSIS, 10, S189 - S189

• An approach to the identification of targets of autoantibodies in multiple sclerosis

  Littleton ET. et al, (2004), JOURNAL OF NEUROIMMUNOLOGY, 154, 91 - 91

• A verbal working memory task reveals new differences in the activation pattern of multiple sclerosis patients compared with healthy controls

  Cader MZ. et al, (2004), MULTIPLE SCLEROSIS, 10, S102 - S103

• The multiple sclerosis monitoring study: Progress to date

  Cooper C. et al, (2004), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 75, 1214 - 1214

• Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis.

  Watson R. et al, (2004), Neurology, 63, 43 - 50

• The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?

  Maggs FG. and Palace J., (2004), Mult Scler, 10, 326 - 329

• Synaptic loss and impaired synaptic plasticity in cortical lesions of multiple sclerosis

  Wegner C. et al, (2004), JOURNAL OF NEUROLOGY, 251, 24 - 24

• Distinct phenotypes of congenital acetylcholine receptor deficiency.

  Burke G. et al, (2004), Neuromuscul Disord, 14, 356 - 364

• The clinical phenotype of non-paraneoplastic voltage gated potassium channel antibody (VGKC Ab) associated CNS disease

  Seymour A. et al, (2004), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 75, 518 - 518

• Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.

  Vincent A. et al, (2004), Brain, 127, 701 - 712

• Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis

  Vincent A. et al, (2004), Brain, 127, 701 - 712

• Potassium channel antibody associated encephalitis: A potentially treatable non-paraneoplastic limbic encephalitis

  Schott JM. et al, (2004), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 75, 519 - 519

• Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study.

  Lily O. et al, (2004), Brain, 127, 269 - 279

• Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.

  Parry AM. et al, (2003), Brain, 126, 2750 - 2760

• The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.

  Pachner AR. et al, (2003), Neurology, 61, S18 - S20

• The measurement of antibodies binding to IFN beta in MS patients treated with IFN beta

  Pachner AR. et al, (2003), NEUROLOGY, 61, S18 - S20

• The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ

  Pachner AR. et al, (2003), Neurology, 61

• Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes.

  Burke G. et al, (2003), Neurology, 61, 826 - 828

• A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.

  Lawrence N. et al, (2003), J Neurol Neurosurg Psychiatry, 74, 1236 - 1239

• Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis

  Cifelli AI. et al, (2003), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 74, 1177 - 1177

• T1 changes detect the progression of pathology in the white matter and cortex of MS patients

  Palace J. et al, (2003), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 74, 1179 - 1179

• Congenital myasthenia - Rapsyn deficiency: How rare?

  Burke G. et al, (2003), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 74, 1181 - 1181

• Autoantibodies as a cause of epilepsy

  Wroe S. et al, (2003), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 74, 1181 - 1181

• MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex.

  Parry A. et al, (2003), J Neuroimaging, 13, 234 - 239

• Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.

  Wylezinska M. et al, (2003), Neurology, 60, 1949 - 1954

• Antibodies to neuronal targets in neurological and psychiatric diseases.

  Vincent A. et al, (2003), Ann N Y Acad Sci, 992, 48 - 55

• The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis

  Dalton C. et al, (2003), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 74, 399 - 399

• Clinical and laboratory characteristics of secondary progressive MS.

  Palace J., (2003), J Neurol Sci, 206, 131 - 134

• Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.

  Parry A. et al, (2003), J Neurol, 250, 171 - 178

• Thalamic neurodegeneration in multiple sclerosis.

  Cifelli A. et al, (2002), Ann Neurol, 52, 650 - 653

• White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis.

  Parry A. et al, (2002), J Neurol, 249, 1279 - 1286

• The UK MS database

  Palace J. et al, (2002), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73, 228 - 228

• Serum autoantibodies against intracellular antigens in multiple sclerosis

  Lily O. et al, (2002), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73, 227 - 227

• Grey matter neuronal loss in multiple sclerosis

  Cifelli A. et al, (2002), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73, 226 - 226

• beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis

  Parry A. et al, (2002), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73, 214 - 214

• Antibodies to voltage gated potassium channels in encephalitis

  Palace J. et al, (2002), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73, 234 - 234

• An unusual case of forearm hyperhidrosis

  Reddel S. et al, (2002), NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 365, R36 - R36

• Intravenous immunoglobulin in neurological disease: a specialist review.

  Wiles CM. et al, (2002), J Neurol Neurosurg Psychiatry, 72, 440 - 448

• Serum autoantibodies to oligodendrocyte and neuronal cell surface antigens in multiple sclerosis patients

  Lily O. et al, (2002), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 72, 137 - 137

• Making the diagnosis of multiple sclerosis.

  Palace J., (2001), J Neurol Neurosurg Psychiatry, 71 Suppl 2, ii3 - ii8

• Myasthenia gravis: diagnostic and management dilemmas.

  Palace J. et al, (2001), Curr Opin Neurol, 14, 583 - 589

• Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis.

  Evangelou N. et al, (2001), Brain, 124, 1813 - 1820

• Myasthenia gravis.

  Vincent A. et al, (2001), Lancet, 357, 2122 - 2128

• PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

  Francis G. et al, (2001), NEUROLOGY, 56, 1628 - 1636

• Randomized controlled trial of interferon-beta-1a in secondary progressive MS - Clinical results

  King J. et al, (2001), NEUROLOGY, 56, 1496 - 1504

• Functional dissection of the anterior cingulate cortex using behavioural correlates with fMRI in the counting stroop.

  Parry A. et al, (2001), NEUROIMAGE, 13, S343 - S343

• Epilepsy: an autoimmune disease?

  Palace J. and Lang B., (2000), J Neurol Neurosurg Psychiatry, 69, 711 - 714

• Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis.

  Evangelou N. et al, (2000), Brain, 123 ( Pt 9), 1845 - 1849

• Axonal loss in the optic nerve and tract in multiple sclerosis

  Esiri M. et al, (2000), BRAIN PATHOLOGY, 10, 643 - 643

• The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis.

  Lee M. et al, (2000), Ann Neurol, 47, 606 - 613

• Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.

  Evangelou N. et al, (2000), Ann Neurol, 47, 391 - 395

• Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis.

  Lee MA. et al, (2000), Arch Neurol, 57, 65 - 70

• Pathogenic autoantibodies to neuronal proteins in neurological disorders.

  Vincent A. et al, (1999), J Neuroimmunol, 100, 169 - 180

• Application of lesion probability maps to analysis of the spatio-temporal evolution of the T2-hyperintense lesions of multiple sclerosis (MS)

  Lee MA. et al, (1999), NeuroImage, 9

• The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

  Tubridy N. et al, (1999), Neurology, 53, 466 - 472

• The effect of anti-α4 integrin antibody on brain lesion activity in MS

  Tubridy N. et al, (1999), Neurology, 53, 466 - 472

• The UK Multiple Sclerosis database.

  Palace J. and Boggild M., (1999), Mult Scler, 5, 297 - 298

• Association of the APOE epsilon4 allele with disease activity in multiple sclerosis.

  Evangelou N. et al, (1999), J Neurol Neurosurg Psychiatry, 67, 203 - 205

• Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: Evidence for distinct mechanisms of lesion genesis?

  Lee MA. et al, (1999), Brain, 122, 1261 - 1270

• Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

  Lee MA. et al, (1999), Brain, 122 ( Pt 7), 1261 - 1270

• Dissociation of 'on-line' and 'off-line' visuomotor control of the arm by focal lesions in the cerebellum and brainstem.

  Liu X. et al, (1999), Neurosci Lett, 264, 121 - 124

• Changes in motor evoked potentials to short-interval paired transcranial magnetic stimuli in multiple sclerosis.

  Ho KH. et al, (1999), Clin Neurophysiol, 110, 712 - 719

• Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

  Lee MA. et al, (1999), Brain, 122 ( Pt 2), 191 - 197

• Distal versus proximal arm tremor in multiple sclerosis assessed by visually guided tracking tasks.

  Liu X. et al, (1999), J Neurol Neurosurg Psychiatry, 66, 43 - 47

• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  (1998), Lancet, 352, 1498 - 1504

• Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.

  Lee MA. et al, (1998), Brain, 121 ( Pt 11), 2095 - 2102

• A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

  Palace J. et al, (1998), Neurology, 50, 1778 - 1783

• A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis

  Palace J. et al, (1998), Neurology, 50, 1778 - 1783

• A radioimmuno-precipitation assay for antibodies to botulinum A.

  Palace J. et al, (1998), Neurology, 50, 1463 - 1466

• New and old treatments for multiple sclerosis.

  Palace J., (1998), Neurologia, 13, 162 - 165

• Distal versus proximal arm tremor in multiple sclerosis assessed by visually guided tracking tasks.

  Liu X. et al, (1998), EUROPEAN JOURNAL OF NEUROSCIENCE, 10, 191 - 191

• Value of sphincter electromyography in the diagnosis of multiple system atrophy.

  Palace J. et al, (1997), Muscle Nerve, 20, 1396 - 1403

• Analysis of action tremor and impaired control of movement velocity in multiple sclerosis during visually guided wrist-tracking tasks.

  Liu X. et al, (1997), Mov Disord, 12, 992 - 999

• Congenital myasthenic syndromes.

  Beeson D. et al, (1997), Curr Opin Neurol, 10, 402 - 407

• New treatments and azathioprine in multiple sclerosis.

  Palace J. and Rothwell P., (1997), Lancet, 350

• How to recognize patients with parkinsonism who should not have urological surgery.

  Chandiramani VA. et al, (1997), Br J Urol, 80, 100 - 104

• Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.

  Motomura M. et al, (1997), J Neurol Sci, 147, 35 - 42

• Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment.

  Glennerster A. et al, (1996), Neurology, 46, 1138 - 1142

• Guillain-Barré syndrome with severe persistent disability: relationship to hyperacute Guillain-Barré syndrome.

  Palace JA. and Hughes RA., (1994), Eur J Neurol, 1, 21 - 27

• Immunogenicity of human recombinant acetylcholine receptor alpha subunit: cytoplasmic epitopes dominate the antibody response in four mouse strains.

  Palace J. et al, (1994), Autoimmunity, 18, 113 - 119

• Primary CNS lymphoma.

  Losseff N. and Palace J., (1993), Br J Hosp Med, 50, 678 - 679

• Clinical and experimental observations in patients with congenital myasthenic syndromes.

  Vincent A. et al, (1993), Ann N Y Acad Sci, 681, 451 - 460

• Isolated dysphagia due to polymyositis.

  Palace J. et al, (1993), Muscle Nerve, 16, 680 - 681

• Letters to the editor

  Singer C. et al, (1993), Muscle & Nerve, 16, 677 - 682

• CLINICAL AND EXPERIMENTAL-OBSERVATIONS IN PATIENTS WITH CONGENITAL MYASTHENIC SYNDROMES

  VINCENT A. et al, (1993), MYASTHENIA GRAVIS AND RELATED DISORDERS : EXPERIMENTAL AND CLINICAL ASPECTS, 681, 451 - 460

• Flecainide induced peripheral neuropathy.

  Palace J. et al, (1992), BMJ, 305

• Stroke following marijuana smoking.

  Barnes D. et al, (1992), Stroke, 23

• Stroke following marijuana smoking

  Barn Es D. et al, (1992), Stroke, 23

• 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.

  Palace J. et al, (1991), J Neurol Neurosurg Psychiatry, 54, 1069 - 1072

• Cryptococcal choroidoretinitis and immunodeficiency.

  Church WH. et al, (1987), Postgrad Med J, 63, 969 - 971

• Mutations in the Mitochondrial Citrate Carrier SLC25A1 are Associated with Impaired Neuromuscular Transmission.

  Chaouch A. et al, J Neuromuscul Dis, 1, 75 - 90

• Disorders of the neuromuscular junction

  Hilton-Jones, David None. and Palace J., Oxford Textbook of Medicine

Recent Publications

• Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.

  Sisay S. et al, (2017), J Neuroimmunol, 306, 40 - 45

• Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

  Jurynczyk M. et al, (2017), Brain, 140, 617 - 627

• Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.

  Tackley G. et al, (2017), J Neurol Neurosurg Psychiatry, 88, 165 - 169

• Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.

  Juryńczyk M. et al, (2017), J Neurol Neurosurg Psychiatry, 88, 132 - 136

• Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

  Geraldes R. et al, (2016), Brain Pathol